A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
Dual targeting of surface receptors with bispecific antibodies is attracting increasing interest in cancer therapy. Here, we present a novel bivalent and bispecific antagonistic molecule (Dab-Fc) targeting human epidermal growth factors 2 and 3 (HER2 and HER3) derived from the Db-Ig platform, which...
Saved in:
Main Authors: | Alexander Rau (Author), Katharina Kocher (Author), Mirjam Rommel (Author), Lennart Kühl (Author), Maximilian Albrecht (Author), Hannes Gotthard (Author), Nadine Aschmoneit (Author), Bettina Noll (Author), Monilola A. Olayioye (Author), Roland E. Kontermann (Author), Oliver Seifert (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The eIg technology to generate Ig-like bispecific antibodies
by: Lennart Kühl, et al.
Published: (2022) -
eIg-based bispecific T-cell engagers targeting EGFR: Format matters
by: Lennart Kühl, et al.
Published: (2023) -
Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization
by: Hui-Fang Zong, et al.
Published: (2022) -
Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
by: Nami Tateyama, et al.
Published: (2022) -
Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model
by: Charles Dahlsson Leitao, et al.
Published: (2020)